XNASARQT
Market cap1.67bUSD
Dec 27, Last price
14.30USD
1D
-4.22%
1Q
52.78%
IPO
-43.10%
Name
Arcutis Biotherapeutics Inc
Chart & Performance
P/E
—
P/S
28.08
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
30.90%
Rev. gr., 5y
%
Revenues
60m
+1,517.09%
Net income
-262m
L-18.41%
CFO
-247m
L-4.14%
Earnings
Feb 25, 2025
Profile
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 59,606 1,517.09% | 3,686 | |||||
Cost of revenue | 115,562 | 305,313 | 207,292 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (55,956) | (301,627) | (207,292) | ||||
NOPBT Margin | |||||||
Operating Taxes | 3,113 | 9,831 | (454) | ||||
Tax Rate | |||||||
NOPAT | (59,069) | (311,458) | (206,838) | ||||
Net income | (262,140) -18.41% | (321,289) 56.04% | (205,902) 51.76% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 98,901 | 191,453 | 210,439 | ||||
BB yield | -44.18% | -23.51% | -20.54% | ||||
| Debt | |||||||
Debt current | 1,470 | 657 | 433 | ||||
Long-term debt | 209,298 | 206,660 | 82,331 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 849 | 25 | |||||
Net debt | (61,093) | (202,272) | (304,295) | ||||
| Cash flow | |||||||
Cash from operating activities | (247,057) | (257,715) | (174,627) | ||||
CAPEX | (428) | (23,283) | (995) | ||||
Cash from investing activities | 180,232 | (87,199) | (75,953) | ||||
Cash from financing activities | 101,323 | 301,798 | 281,947 | ||||
FCF | (71,739) | (310,759) | (206,774) | ||||
| Balance | |||||||
Cash | 271,861 | 409,589 | 387,059 | ||||
Long term investments | |||||||
Excess cash | 268,881 | 409,405 | 387,059 | ||||
Stockholders' equity | (981,891) | (720,844) | (408,556) | ||||
Invested Capital | 1,278,058 | 1,132,968 | 783,815 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 69,305 | 55,032 | 49,406 | ||||
Price | 3.23 -78.18% | 14.80 -28.64% | 20.74 -26.27% | ||||
Market cap | 223,857 -72.52% | 814,478 -20.51% | 1,024,672 2.13% | ||||
EV | 162,764 | 612,206 | 720,377 | ||||
EBITDA | (54,435) | (300,693) | (206,838) | ||||
EV/EBITDA | |||||||
Interest | 29,712 | 15,652 | |||||
Interest/NOPBT | |||||||